Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5021-5040

  Malamas, Michael S ^a   Manas, Eric S ^a   McDevitt, Robert E ^a   Gunawan, Iwan ^a   Xu, Zhang B ^a   Collini, Michael D ^a   Miller, Chris P ^b   Dinh, Tam ^c   Henderson, Ruth A ^a   Keith Jr , James C ^a   Harris, Heather A ^a  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Wyeth Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 FLUORO 4 HYDROXYPHENYL) 7 VINYL 5 BENZOXAZOLOL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BAZEDOXIFENE; BENZOXAZOLE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA AGONIST; ETHINYLESTRADIOL; FLUTAMIDE; HLA B27 ANTIGEN; PROPYLPYRAZOLETRIOL; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BINDING AFFINITY; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENTERITIS; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; ORGAN WEIGHT; OSTEOPENIA; PROSTATE; RAT; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; UTERUS WEIGHT; VASOMOTOR DISORDER; X RAY CRYSTALLOGRAPHY;

ANDROGEN ANTAGONISTS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; BODY TEMPERATURE; BONE DISEASES, METABOLIC; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ESTROGEN RECEPTOR BETA; FEMALE; HLA-B27 ANTIGEN; HUMANS; ISOXAZOLES; MALE; MICE; MODELS, MOLECULAR; ORGAN SIZE; PHENOLS; PROSTATE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; UTERUS;

EID: 4744376265     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049719y     Document Type: Article

References (49)

1. (a) Toran-Allerand, C. D. J. Steroid Biochem. Mol. Biol. 1996, 56, 169-178.
2. (b) Kuiper, G. G. J. M.; Carlquist, M.; Gustafsson, J.-A. Sci. Med. (Philadelphia) 1998, 5, 36-45.
3. (c) Ritzen, E. M.; Nilsson, O.; Holst, M.; Savendahl, L.; Wroblewski, J. J. Steroid Biochem. Mol. Biol. 2000, 74, 383-386.
4. (d) Abney, T. O. Mol. Androl. 1992, 4, 281-289.
5. Tsai, M. J.; O'Malley, B. W. Molecular Mechanisms of Action of Steroid/Thyroid Receptors Superfamily Members. Annu. Rev. Biochem. 1994, 63, 451-486.
6. Green, S.; Walter, P.; Kumar, V.; Krust, A.; Bornert, J. M.; Argos, P.; Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320, 134-139.
7. Kuiper, G. G. J. M.; Enmark E., Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5925-5930.
8. (a) Mowa, C. N.; Iwanaga, T. J. Endocrinology 2000, 165, 59-66.
9. (b) Shughrue, P. J.; Lane, M. V.; Merchenthaler, I. J. Comput. Neurol. 1997, 388, 507-525.
10. (c) Bord, S.; Horner, A. J. Clin. Endocrinol Metab. 2001, 86, 2309-14.
11. (d) Saji S.; Jensen, E. V.; Nilsson, S.; Rylander, T.; Warner, M.; Gustafsson, J. A. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 337-42.
12. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, Bonn, T.; Thorsell, A. G.; Engstrom, O.; L-junggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4619.
13. Harris, H. A.; Albert, L. M.; Leathurby, Y.; Malamas, M. S.; Mewshaw, R. E.; Miller, C. P.; Kharode, Y. P.; Marzolf, J.; Komm, B. S.; Winneker, R. C.; Frail, D. E.; Hederson, R. A.; Zhu, Y.; Keith, J. C., Jr. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 2003, 144, 4241-4249.
14. Harris, H, A.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Characterization of the biological roles of the estrogen receptors, ER alpha and ER beta, in estrogen target tissues in vivo through the use of an alpha-selective ligand. Endocrinology 2002, 143, 4172-4177.
15. (a) Kuiper, G. G. J. M.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, H.; Saag, P. T.; Burg, B.; Gustafsson, J. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998, 139, 4252-4263.
16. (b) Miller, C. P.; Collini, M. D.; Harris, H. A.; Constrained phytoestrogens and analogues as ERβ sélective ligands. Bioorg. Med. Chem. Lett. 2003, 13, 2399-2403.
17. Barlaam, B. C.; Piser, T. M. PCT Int. Appl. WO 0062765, 2000.
18. Meyers, M. J.; et al. Estrogen receptor-beta potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 2001, 44, 4230-4251.
19. Sun, J.; Baudry, J.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand diarylpropionitrile. Mol. Endocrinol. 2003, 17, 247-258.
20. (a) Korach, K. S.; Sarver, O.; Chae, K.; McLachlan, J. A.; McKinney, J. D. Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: conformationally restricted structural probes. Mol. Pharmacol. 1998, 33, 120-126.
21. (b) Edsall, R. J.; Harris, H. A.; Manas, E. S.; Mewshaw, R. E. ER beta ligands. Part 1: The discovery of ER beta selective ligands which embrace the 4-hydroxy-biphenyl template. Bioorg. Med. Chem. 2003, 11, 3457-3474.
22. Barlaam, B.; Bernstein, P.; Dantzman, C.; Warwick, P. Preparation of benzoxazoles and benzothiazoles as selective ligands for human b-estrogen receptor. In PCT Int. Appl. 71 pp. (Astra-Zeneca AB, Sweden). WO 2002051821, 2002.
23. Bernstein, P. Preparation of aminobenzothiazoles as selective ER-β ligands for treatment of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis or prostate cancer. In PCT Int. Appl. 30 pp. (Astra-Zeneca A. B., Sweden). WO 2003045930, 2003.
24. Meyers, M. J.; Sun, J.; Carlson, K. E.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis-and trans-5,11-dialkyl-5,6,11,12- tetrahydrochrysenes. J. Med. Chem. 1999, 42, 2456-2468.
25. Sun, J.; et al. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999, 140, 800-804.
26. Shiau, A. K.; et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 2002, 9, 359-64.
27. Schopfer, U.; Schoeffter, P.; Bischoff, S. F.; Nozulak, J.; Feuerbach, D.; Floersheim, P. Toward selective ER beta Agonists for central nervous system disorders: Synthesis and characterization of aryl benzthiophenes. J. Med. Chem. 2002, 45, 1399-1401.
28. Katzenellenbogen, J. A.; et al. Preparation of nonsteroidal estrogen receptor subtype-selective ligands. In PCT Int. Appl., 134 pp. (Board of Trustees of the University of Illinois). WO 2000019994; 2000.
29. Huebner, V. D.; et al. Preparation of substituted isoxazoles as estrogen receptor modulators. In PCT Int. Appl., 115 pp. ((Chiron Corporation, USA). WO 2000008001, 2000).
30. Barlaam, B.; Dock, S.; Folmer, J. Preparation of benzimidazoles as selective estrogen receptor-b ligand. In PCT Int. Appl., 46 pp. (Astrazeneca AB, Sweden). WO 2002046168; 2002.
31. Henke, B. R.; et al. A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. J. Med. Chem. 2002, 45, 5492-5505.
32. Yang, W.; Wang, Y.; Ma, Z.; Golla, R.; Stouch, T.; Seethala, R.; Johnson, S.; Gungor, T.; Feyen, J. H. M.; Dickson, J. K., Jr. Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists. Bioorg. Med. Chem. Lett., in press, 2004.
33. (a) Parker, D. L., Jr.; Ratcliffe, R. W.; Wilkening, R. R.; Wildonger, K. J. PCT Int. Appl. WO 0182923, 2001.
34. (b) Wilkening, R. R.; Parker, D. L., Jr.; Wildonger, K. J.; Meng, D.; Ratcliffe, R. W. PCT Int. Appl. WO 0241835, 2002.
35. Manas, E. S.; et al., J. Am. Chem. Soc., in press, 2004.
36. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
37. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
38. Eddarir, S.; Mestdagh, H.; Rolando, C. Synthesis of fluorinated enynes and dienes via 1-bromo-2-fluoro alkenes. Tetrahedron Lett. 1991, 32, 69
39. Rieke, R. D.; Hanosn, M. V. New organometalic reagents using highly reactive metals. Tetrahedron 1997, 53, 1925.
40. Harris, H. A.; Bapat, A. R.; Gonder, D. S.; Frail; D. E. Steroids 2002, 67, 379-384.
41. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Nature 1997, 389, 753-758.
42. Harris, H. A.; Henderson, R. A.; Bhat, R. A.; Komm, B. S. Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells. Endocrinology 2001, 142, 645-652.
43. Miller, C. P.; Collini, M. D.; Tran, B. D.; Harris, H. A.; Kharode, Y. P.; Marzolf, J. T.; Moran, R. A.; Henderson, R. A.; Bender, R. H.; Unwalla, R. J.; Greenberger, L. M.; Yardley, J. P.; Abou-Gharbia, M. A.; Lyttle, C. R.; Komm, B. S. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J. Med. Chem. 2001, 44, 1654-1657.
44. Shughrue, P. J.; Askew, G. R.; Dellovade, T. L.; Merchenthaler, I. Estrogen-binding sites and their functional capacity in estrogen receptor double knockout mouse brain. Endocrinology 2002, 143, 1643-1650.
45. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Design. 1997, 11, 333-44.
46. Merchenthaler, I.; Funkhouser, J. M.; Carver, J. M.; Lundeen, S. G.; Ghosh, K.; Winneker, R. C. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998, 30, 307-316.
47. (a) Zhang, W. H.; Makela, S.; Andersson, L. C.; Salmi, S.; Saji, S.; Webster, J. I.; Jensen, E. V.; Nilsson, S.; Warner, M.; Gustafsson, J. A. A role for estrogen receptors in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6330-6335.
48. (b) Corey, E.; Quinn, J. E.; Emond, M. J.; Buhler, K. R.; Brown, L. G.; Vessella, R. L. Inhibition of androgen-independent growth of prostate cancer xenografts by 17 beta-estradiol. Clin. Cancer Res. 2002, 8, 1003-1007.
49. (c) Leav, I.; Lau, K. M.; Adams, J. Y.; McNeal, J. E.; Taplin, M. E.; Wang, J. F.; Singh, H.; Ho, S. M. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 2001, 259, 79-92.